BioMarin Pharmaceutical Inc. (BMRN) - Stock Analysis
Last updated: Mar 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
BioMarin Pharmaceutical raised 2025 revenue guidance on strong product sales and a $4.8B accretive Amicus acquisition, supported by FDA regulatory catalysts and an 18% stock gain over 3 weeks, validating near-term positive momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong cash generation ⢠Q4 earnings hit ⢠Elevated operating spend BMRN delivered strong FY2025 cash generation, high gross margins and low leverage but a Q4 loss, heavy ongoing operating spend, sizable working-capital exposure and rich valuation that heighten near-term downside risk.
Price Behavior
Key Price Behavior Insights: ⢠Above last month SMA ⢠Neutral momentum ⢠Resistance test risk Support Level: $57â$58 Resistance Level: $62.6â$64.1 Price sits modestly above its last month SMA (~$60.6) indicating a mild short-term uptrend with neutral RSI (~55), resistance ~$62.6â$64.1 and immediate support ~$57â$58, where failure to reclaim resistance would likely invite a retest of support.
Sentiment & News
Key News Insights: ⢠Revenue growth ⢠Roctavian withdrawal ⢠Amicus acquisition BioMarin delivered revenue and EPS beats driven by VOXZOGO and a PALYNZIQ label win, but the quarter was overshadowed by a voluntary Roctavian withdrawal, an Amicus acquisition announcement, and an $850M debt raise. #M&Aâ
AI Summary
BioMarin has shifted from a singleâasset biotech to a hybrid commercial cashâflow engineâVOXZOGO growth plus the Amicus deal are now the primary drivers of valuation rather than blueâsky pipeline upside. Key actionable risk to monitor: successful, clean Amicus close and nearâterm nonâGAAP margin/FCF improvement (and stable interest coverage given new debt) are required to justify the current premium, while integration/legal issues, earnings volatility, or VOXZOGO access setbacks would quickly compress multiples.
Description
BioMarin Pharmaceutical is a biopharmaceutical company that develops and sells therapies for rare and serious genetic and metabolic disorders, with marketed treatments across lysosomal storage disorders, phenylketonuria, Batten disease, achondroplasia and related conditions. Its late-stage pipeline includes gene therapies for hemophilia A and phenylketonuria and early-stage programs for primary hyperoxaluria, while commercial operations distribute products through specialty pharmacies, hospitals and wholesalers in the U.S., Europe, Latin America and other markets. The company maintains multiple licensing and collaboration arrangements and is headquartered in San Rafael, California, having been founded in 1996.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 22 | Dec 29 | BMRN | BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical raised 2025 revenue guidance on strong product sales and a $4.8B accretive Amicus acquisition, supported by FDA regulatory catalysts and an 18% stock gain over 3 weeks, validating near-term positive momentum. | Closed | +1.3% |